Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. SenzaGen AB
  6. News
  7. Summary
    SENZA   SE0010219626

SENZAGEN AB

(SENZA)
SummaryQuotesChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

SenzaGen : receives SEK 0.4 m order for GARD«skin and GARD«air tests from pharmaceutical company H. Lundbeck A/S

12/02/2020 | 02:31am EDT

SenzaGen has been selected to test compounds from H. Lundbeck A/S. Valued at SEK 0.4 million, the project includes both GARD®skin and GARD®air. The tests will be performed in SenzaGen’s GLP-certified laboratory in Lund.

A new collaboration is being announced with H. Lundbeck A/S, a global pharmaceutical company covering the full value chain from research and development to production and promotion of treatments of disorders within CNS. The company aims to use the combination of GARD tests, which SenzaGen is unique in being able to offer, to determine whether new development candidates have sensitizing properties.

“In spite of the challenges presented by the ongoing pandemic, we continue to establish the GARD technology among international customers. We are very pleased that after a thorough evaluation based on several interactions and presentations, Lundbeck has chosen to collaborate with SenzaGen and that they have decided to test compounds with both GARDair and GARDskin. The order illustrates that our direct contacts with large international companies continue to bear fruit, and means that we, during the year, will have run tests for customers in all the major industries we cater to – pharmaceuticals, medical devices, cosmetics and chemicals,” says Axel Sjöblad, CEO of SenzaGen.

“Lundbeck is pleased to initiate this collaboration with SenzaGen. The introduction of new innovative assays such as the GARD tests is part of our commitment to constantly expand our expertise in safety testing. By doing this, we pursue our goals of providing a safe and healthy work environment for our employees and improving the quality of life for people living with brain disorders,” says Allan Dahl Rasmussen, Director of Regulatory Toxicology in Lundbeck.

With excellent predictivity, the GARD® technology improves the quality of customers’ decision-making and contributes to increased product safety while reducing the number of animal tests.

© Modular Finance, source Nordic Press Releases

Stocks mentioned in the article
ChangeLast1st jan.
H. LUNDBECK A/S 0.83% 193.5 Delayed Quote.-8.09%
SENZAGEN AB -6.83% 19.1 Delayed Quote.56.49%
All news about SENZAGEN AB
07/26SENZAGEN : Positive scientific ESAC opinion on GARD«skin paves the way for OECD ..
AQ
07/26SenzaGen AB Receives Positive ESAC Opinion for GARD«Skin as the First Genomic..
CI
07/12SENZAGEN : and RIFM begin part two of the GARD«skin Dose-Response program
AQ
07/12SenzaGen Launches Part Two of Project Together with the Research Institute fo..
CI
07/09SENZAGEN : receives SEK 0.65 million order for GARD«skin Dose-Response from one ..
AQ
07/09SenzaGen AB Receives SEK 0.65 Million Order for Gard«Skin Dose-Response
CI
05/24SENZAGEN : expands services within in vitro skin toxicology
AQ
05/05SENZAGEN : Report from AGM of SenzaGen AB on 5 May 2021
AQ
03/25SENZAGEN : Annual Report 2020 published
AQ
03/04BIOSTOCK STUDIO : SenzaGen is aiming to increase market activity in 2021
AQ
More news
Financials
Sales 2020 7,96 M 0,92 M 0,92 M
Net income 2020 -27,2 M -3,15 M -3,15 M
Net cash 2020 89,3 M 10,4 M 10,4 M
P/E ratio 2020 -10,3x
Yield 2020 -
Capitalization 438 M 50,8 M 50,8 M
EV / Sales 2019 56,6x
EV / Sales 2020 23,9x
Nbr of Employees 17
Free-Float 61,1%
Chart SENZAGEN AB
Duration : Period :
SenzaGen AB Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
Axel Sj÷blad Chief Executive Officer
Marianne Olsson Chief Financial Officer
Karl Arne Krister Borrebaeck Chairman
Henrik Johansson Chief Scientific Officer
Maria Agemark Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
SENZAGEN AB56.49%51
EXACT SCIENCES CORPORATION-20.12%18 197
GUARDANT HEALTH, INC.-11.66%11 513
BGI GENOMICS CO., LTD.-9.67%7 362
INVITAE CORPORATION-26.05%6 179
ADAPTIVE BIOTECHNOLOGIES CORPORATION-36.82%5 242